Armed ImmunoCytokine Platform, AIC™

Based on deep understanding of immunology and the ...

more >>

Armed Innate-effector Multispecific Platform, AIM™

By activation of innate effectors (i.e. NK and γδT...

more >>

ADCC Enhanced Antibody Platform, AEA™

Fucose modification is one of the most important f...

more >>
About SunHo
  • 20+

    innovative and differentiated R&D pipelines
  • 150

  • 85

    R&D members with 70% of master degree and above
  • 4500

    square meters of workshop
more >>


SUNHO (China) BioPharmaceutical Co., Ltd. (hereinafter referred to as SunHo) is located in Nanjing Economic and Technological Development Zone, Jiangsu Province, China. SunHo is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative biotherapeutics and focuses on the field of cancer immunotherapy, autoimmune diseases and neurodegenerative diseases.

With multiple proprietary and patented platforms, such as Armed ImmunoCytokine Platform (AIC™) , Armed Innate-effector Multispecific Platform (AIM™) , ADCC Enhanced Antibody Platform (AEA™), SunHo has developed more than 20 globally innovative and differentiated R&D pipelines in oncology/immunology with 4 in clinical stage, 4 in IND application, 6 in preclinical, and many innovative projects in the early R&D stage. We are striving to develop the next generation and best-in-class medicines to address unmet medical needs with accessibility globally.......